WPP creates WPP Health & Wellness; Publicis Health formalizes new name; 10 ways healthcare companies are testing Instagram
Biogen completes hemophilia spinoff; old drug being tested as a prostate cancer treatment; Merck reports Q4 decline in revenue
Sanofi, Regeneron denied bid to overturn Amgen win in patent case; Abbott to close St. Jude deal; Gilead hires SVP of hematology and oncology
Biogen names new CEO; the FDA issues two warning letters; Allergan to acquire aesthetics firm
BMS to pay $19.5 million to settle marketing violations for Abilify; AstraZeneca to cut 700 U.S. jobs; Trump reportedly considering Jim O'Neill to lead FDA
J&J in talks to buy Actelion; Novo Nordisk pulls ads on Breitbart News; Takeda to market Ninlaro in Europe
J&J's experimental RA drug has mixed results in clinical trial; Novartis reportedly considers buying generics maker; Donald Trump names healthcare transition team leader
GSK files for FDA approval of shingles vaccine; Chinese drugmaker reportedly files for largest IPO since 2013; Sunovion completes deal to buy Cynapsus
Pure Communications CEO Andrea Johnston will lead the combined agency.
Pfizer to acquire cancer drugmaker Medivation; Valeant names new CFO; Apple acquires health data startup
IBM develops chip to detect early stages of cancer; Theranos plans to develop a "minilab;" Aetna and Humana to sell $117 million in assets
Omnicom recently reorganized its health agencies under the Omnicom Health Group umbrella.
The scientific services company expands its portfolio to include expertise in oncology clinical studies.
Teva acquires sensor-based inhaler; EU conditionally approves Amgen's cancer drug, Blincyto; Novartis CEO says targeted therapies may reduce unnecessary US healthcare spending
Walgreens Boots Alliance's global comms team works hand in hand to balance the complexities of a merger and create a unified strategy to inspire all stakeholders.
CVS excludes 31 drugs including Viagra from its 2016 formulary; Sanofi partners with Evotec on stem-cell treatment development; primary-care physicians may hesitate to prescribe Truvada for PrEP
The FDA updates Gilenya's label over definite case of PML; generic drug companies are consolidating for negotiating power; the FDA revises guidance on DTC risk information
Shire offers to buy Baxalta for $30 billion; CVS reports strong sales in specialty pharmacy; Reuters reports that new drug launches hit 17-year high in 2014
Copaxone sales rise despite generic competition; Valeant to defend tax strategy; Bristol-Myers Squibb to test Opdivo with mogamulizumab in the US
Sanofi plans immuno-oncology collaboration with Regeneron; Merck considers hard-to-treat patient populations for its experimental hepatitis-C therapy; drugmakers did not report 10% of adverse events to the FDA within required timeframe
Teva will acquire Allergan's generic drug business; AstraZeneca sells rights to cancer drug to Sanofi; the FDA approves two drugs heading into the weekend
Experimental Alzheimer's disease drugs produce mixed results; court rules in favor of Novartis in Zarxio case; Horizon Pharma increases its bid for Depomed
Gilead will limit financial assistance to patients to pressure payers; Biogen reports another PML case related to Tecfidera; Valeant buys Egyptian drugmaker
Celgene announces $7.2-billion bid for Receptos; Cytokinetics is using Ice Bucket Challenge donations to test experimental drug; GlaxoSmithKline conducts media review for its consumer health brands
Groups urge disclosure of payments to nurse practitioners and physician assistants; Horizon seeks $3-billion acquisition of Depomed; Sanofi closes $245-million agreement to buy priority-review voucher
Fourth and fifth members of network add healthcare advertising and PR expertise.
Novo Nordisk replaces Sanofi as the top marketer of metabolic drugs; Actavis changed its name to Allergan; access to Medicare Part D has not reduced overall Medicare costs
CVS will buy institutional pharmacy Omnicare in a $12.7-billion deal; ProPublica says the FDA and GlaxoSmithKline failed to protect patients from misusing Advair; Regeneron and Sanofi expect to file RA drug sarilumab with the FDA in the fourth quarter of this year
Perrigo says a Mylan deal is possible; new guidelines may reduce cancer screenings; Takeda petitions dictionaries to add a new definition for depression
Mylan considers higher bid for Perrigo; Boehringer Ingelheim partners with health system on COPD; EMD Serono's experimental cancer drug gets Fast Track status
- In Merck video, woman says a cure is the greatest invention
- Five things for pharma marketers to know: Tuesday, April 18, 2017
- Five things for pharma marketers to know: Monday, April 24, 2017
- Five things for pharma marketers to know: Thursday, April 20, 2017
- Five things for pharma marketers to know: Wednesday, April 19, 2017